Advertisement

The Role of Pharmacokinetics and Pharmacodynamics in the Development of Therapeutic Proteins

  • Joyce Mordenti
  • James D. Green
Part of the NATO ASI Series book series (NSSA, volume 221)

Abstract

Since the degree of preclinical work conducted to address safety issues in animals is usually rate limiting to the initiation of Phase I clinical studies, the preclinical program should be designed to allow rapid entry into the clinic without compromising safety. The establishment of acceptable therapeutic ratios relies on the relationship of doses utilized in toxicology studies and their projected relationship to the clinical dosing regimen. Experience with multiple therapeutic proteins (biomacromolecules) in our laboratory indicates that the pharmacokinetic behavior of many proteins is predictable across species. In selected cases, this information permits extrapolation of preclinical safety and efficacy data to the clinical setting when doses are related on the basis of pharmacokinetic equivalence rather than on a body weight (mg/kg) or body surface area (mg/m2) basis. With a better understanding of this cross species relationship, the confidence in the safety of a therapeutic agent in initial clinical studies is increased. Based on our experience, an approach is presented that maximizes the relevance of the preclinical information gained, minimizes the scope of the initial toxicology studies, and, therefore, minimizes time to initiation of Phase I. This strategy may be useful for selected classes of compounds. Also, several case studies are presented to illustrate how pharmacokinetics was used to bridge the gap between discovery research, preclinical studies, and clinical trials during the development of two therapeutic proteins (rCD4 and rCD4-IgG) for the treatment of Acquired Immunodeficiency Syndrome (AIDS).

Keywords

Therapeutic Protein Dose Selection Allometric Exponent Preclinical Safety Allometric Approach 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Boxenbaum H., 1984. Interspecies Pharmacokinetic Scaling and the Evolutionary-Comparative Paradigm. Drug Metab. Rev. 15: 1071.Google Scholar
  2. Boxenbaum H. and D’Souza R.W., 1990. Interspecies Pharmacokinetic Scaling, Biological Design, and Neoteny. In: “Advances in Drug Research,” Volume 19, page 139. Academic Press, London.Google Scholar
  3. Byrn R.A., Mordenti J., Lucas C., Smith D., Marsters S., Johnson J., Cossum P., Chaniow S., Wurm F., Gregory T., Groopman J., Capon D., 1990. Biological Properties of a CD4 Immunoadhesin. Nature 344: 667.PubMedCrossRefGoogle Scholar
  4. Byrn R.A., Sekigawa I., Chamow S.M., Johnson J.S., Gregory T.J., Capon D.J., Groopman J.E., 1989. Characterization of In Vitro Inhibition of Human Immunodeficiency Virus by Purified Recombinant CD4. J. Vitol. 63: 4370.Google Scholar
  5. Calder III W. A., 1984. “Size, Function, and Life History.” Harvard University Press, Cambridge, MA.Google Scholar
  6. Capon D. J., Chamow S.M., Mordenti J., Marsters S.A., Gregory T., Mitsuya H., Byrn R.A., Lucas C., Wurm F.M., Groopman J.E., Broder S, Smith D.H., 1989. Designing CD4 Immunoadhesins for AIDS Therapy. Nature 337: 525.PubMedCrossRefGoogle Scholar
  7. Chappell W.R. and Mordenti J., 1991. Extrapolation of Toxicological and Pharmacological Data from Animals to Humans. In: “Advances in Drug Research ( B. Testa ed.), Volume 20, page 1. Academic Press Inc., San Diego, CA.Google Scholar
  8. Collier A., Katzenstein D., Coombs R., Holodniy M., Mordenti J., Arditti D., Ammann A., Merigan T., Corey L., 1990. Safety and Pharmacokinetics of Intravenous Recombinant CD4 Immunoadhesin (rCD4-IgG) (AIDS Clinical Trials Protocol 121), Abstract S.B.480. Proc. Sixth International Conference on AIDS, San Francisco, CA, Vol 3, page 206. (Serum concentration data subsequently corrected by a factor of 1. 44 ).Google Scholar
  9. Collins J.M., Grieshaber C.K., Chabner B.A., 1990. Pharmacologically-Guided Phase I Clinical Trials Based Upon Preclinical Drug Development. J. Nat.Cancer Inst. 82: 1321.PubMedCrossRefGoogle Scholar
  10. Collins J.M., Leyland-Jones B., Grieshaber C.K., 1987. Role of Preclinical Pharmacology in Phase I Clinical Trials: Considerations of Schedule-Dependence. In: “Concepts in Cancer Chemotherapy” ( F.M. Muggia, ed), page 129. Martinus Nijhoff, Boston.Google Scholar
  11. Collins J.M., Zaharko D.S., Dedrick R.L., Chabner B.A., 1986. Potential Roles for Preclinical Pharmacology in Phase I Clinical Trials. Cancer Treat. Rep. 70: 73.Google Scholar
  12. Fromson J.M., 1989. Perspectives in Pharmacokinetics: A Phased Approach to Drug Development. J. Pharm. Biopharm. 17: 509.CrossRefGoogle Scholar
  13. Green J.D., 1990. Preclinical Safety Evaluation Strategy For Biomacromolecules - A Perspective. Abstract in: “From Clone To Clinic. An International Meeting on the Development of Biotechnological Products for Use in Humans.” RAI Congress Centre Amsterdam, the Netherlands, page 39.Google Scholar
  14. Green J.D., and Mordenti J., 1990. Rational Basis for Dose Selection in Preclinical and Clinical Safety Assessment, Abstract 876. Toxicologist 10: 219.Google Scholar
  15. Harbour C. and Woodhouse G., 1990. Viral Contamination of Monoclonal Antibody Preparations: Potential Problems and Possible Solutions. Cytotechnology 4: 3.PubMedCrossRefGoogle Scholar
  16. Harris R. J., Wagner K. L., and Spellman, M. W., 1990. Structural Characterization of Recominant CD4-IgG Hybrid Molecule. Eur. J. Biochem. 194: 611.PubMedCrossRefGoogle Scholar
  17. Janeway C.A.J., 1988. Accessories or Coreceptors? Nature 335: 208.PubMedCrossRefGoogle Scholar
  18. Kahn J. O., Davis A. J., Groopman J. E., Kaplan L. D., Sherwin S. A., Volberding P. A., 1989. Pharmacokinetic Studies of Recombinant Soluble CD4 in Patients with AIDS and AIDS Related Complex, Abstract Th.B.0.5. Proc. Fifth International Conference on AIDS, Montreal, Cananda, page 212. (Pharmacokinetic data in abstract were preliminary; data in table are final results.)Google Scholar
  19. Kahn J. O., Allan J. D., Hodges T. L., Kaplan L. D., Arri C. J., Fitch H. F., Izu A. E., Mordenti J., Sherwin S. A., Groopman J. E., Volberding P. A., 1990. The Safety and Pharmacokinetics of Recombinant Soluble CD4 (rCD4) in Subjects with the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-related Complex: A Phase I Study. Annals Int. Med. 112: 254.Google Scholar
  20. Kleiber M., 1950. Physiological Meaning of Regression Equations. J. Appl. Physiol. 2: 417.Google Scholar
  21. Lasagna L., 1989. Congress, the FDA, and New Drug Development: Before and After 1962. Persp. Biol. Med. 32: 322.Google Scholar
  22. Maddon P.J., Dalgleish A.G., McDougal J.S., Clapham P.R., Weiss R.A., Axel R., 1986. The T4 Gene Encodes the AIDS Virus Receptor and is Expressed in the Immune System and the Brain. Cell 47: 333.PubMedCrossRefGoogle Scholar
  23. McMahon T.A. and Bonner J.T., 1983. On Size and Life. Scientific American Books, New York.Google Scholar
  24. Mordenti J., 1986a. Dosage Regimen Design for Pharmaceutical Studies Conducted in Animals. J. Pharm. Sci. 75: 852.PubMedCrossRefGoogle Scholar
  25. Mordenti J., 1986b. Man versus Beast: Pharmacokinetic Scaling In Mammals. J. Pharm. Sci. 75: 1028.PubMedCrossRefGoogle Scholar
  26. Mordenti J. and Chappell W., 1989. The Use of Interspecies Scaling in Toxicokinetics. In: “Toxicolcinetics and New Drug Development” ( A. Yacobi, J. Skelly, V. Bata, eds.), page 42. Pergamon Press, New York.Google Scholar
  27. Mordenti J., Chen S., Moore J., Ferraiolo B., 1990. Total Body Clearance of Recombinant and Synthetic Proteins are Well Described by an Allometric Relationship, Abstract 955. Toxicologist 10: 239.Google Scholar
  28. Mordenti J., Chen S., Moore J., Ferraiolo B., Green, J. D., 1991. Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins. Pharmaceutical Research, Val 1 (Nov.), in press.Google Scholar
  29. Mordenti J., Shaieb D., Chow P., Cossum P., Ferraiolo B., Lewandowski M., Moore J., Green J. D., 1991. Preclinical Safety Evaluation Strategy for Biomacromolecules — A Perspective. In: “Safety Assessment for Pharmaceuticals” (Shayne C. Gad, Ed.). Van Nostrand Reinhold, New York, NY (in press).Google Scholar
  30. Office of Biologics Research and Review, 1987. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use, Office of Biologics Research and Review, Center for Drugs and Biologics, Food and Drug Administration, U.S.A., June 1, 1987.Google Scholar
  31. Peck C., Collins J. Harter J., 1990. Incorporation of Pharmacokinetic and Pharmacodynamic Intelligence into Early Drug Development, Abstract PP-3. Clin. Phannacol. Ther. 47: 126.Google Scholar
  32. Sattentau Q. and Weiss R., 1988. The CD4 Antigen: Physiological Ligand and HIV Receptor. Cell 52: 631.PubMedCrossRefGoogle Scholar
  33. Schmidt-Nielsen K., 1984. Scaling: Why is Animal Size So Important? Cambridge University Press, New York.Google Scholar
  34. Smith D.H., Bym R.A., Marsters S.A., Gregory T., Groopman J.E., Capon D.J., 1987. Blocldng of HIV-1 Infectivity by Soluble, Secreted Form of the CD4 Antigen. Science 238: 1704.PubMedCrossRefGoogle Scholar
  35. Yarchoan R., Thomas R. V., Pluda J. M., Perno C. F., Mitsuya H., Marczyk K. S., Sherwin S. A., Broder S., 1989. Phase I Study of the Administration of Recombinant Soluble CD4 (rCD4) by Continuous Infusion to Patients with AIDS or ARC, Abstract M.C.P. 137. Proc. Fifth International Conference on AIDS, M.ntreal, Canada, page 564. (Pharmacoldnetic data in abstract were preliminary; data in table are final results.)Google Scholar
  36. Yarchoan R., Pluda J. M., Adamo D., Thomas R. V., Mordenti J., Goldspiel B. R., Ammann A., Broder S., 1990. Phase I Study of rCD4-IgG Administered by Continuous Intravenous (IV) Infusion to Patients with AIDS or ARC, Abstract S.B.479. Proc. Sixth International Conference on AIDS, San Francisco, CA, Vol 3, Page 205. (Serum concentration data subsequendy corrected by a factor of 1. 44 ).Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Joyce Mordenti
    • 1
  • James D. Green
    • 1
  1. 1.Department of Safety EvaluationGenentech, Inc.South San FranciscoUSA

Personalised recommendations